Advertisement

AIDS and Behavior

, Volume 22, Issue 3, pp 971–985 | Cite as

Substance Use, Violence, and Antiretroviral Adherence: A Latent Class Analysis of Women Living with HIV in Canada

  • Allison Carter
  • Eric Abella Roth
  • Erin Ding
  • M-J Milloy
  • Mary Kestler
  • Shahab Jabbari
  • Kath Webster
  • Alexandra de Pokomandy
  • Mona Loutfy
  • Angela KaidaEmail author
  • Behalf of the CHIWOS Research Team
Original Paper

Abstract

We used latent class analysis to identify substance use patterns for 1363 women living with HIV in Canada and assessed associations with socio-economic marginalization, violence, and sub-optimal adherence to combination antiretroviral therapy (cART). A six-class model was identified consisting of: abstainers (26.3%), Tobacco Users (8.81%), Alcohol Users (31.9%), ‘Socially Acceptable’ Poly-substance Users (13.9%), Illicit Poly-substance Users (9.81%) and Illicit Poly-substance Users of All Types (9.27%). Multinomial logistic regression showed that women experiencing recent violence had significantly higher odds of membership in all substance use latent classes, relative to Abstainers, while those reporting sub-optimal cART adherence had higher odds of being members of the poly-substance use classes only. Factors significantly associated with Illicit Poly-substance Users of All Types were sexual minority status, lower income, and lower resiliency. Findings underline a need for increased social and structural supports for women who use substances to support them in leading safe and healthy lives with HIV.

Keywords

Substance use Violence Antiretroviral adherence HIV/AIDS Women 

Notes

Acknowledgements

The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS) Research Team would like to especially thank all of the women living with HIV who participate in this research. We also thank the entire national team of Co-Investigators, Collaborators, and Peer Research Associates. We would like to acknowledge the national Steering Committee, the three provincial Community Advisory Boards, the national CHIWOS Aboriginal Advisory Board, and our partnering organizations for supporting the study, especially those who provide interview space and support to our Peer Research Associates.

Funding

CHIWOS is funded by the Canadian Institutes of Health Research (CIHR, MOP111041); the CIHR Canadian HIV Trials Network (CTN 262); the Ontario HIV Treatment Network (OHTN); and the Academic Health Science Centres (AHSC) Alternative Funding Plans (AFP) Innovation Fund. AC received support from a CIHR Doctoral Award. AdP received support from Fonds de Recherche du Quebéc – Santé (FRQS) (Chercheur-boursier clinicien – Junior 1). AK received salary support through a Tier 2 Canada Research Chair in Global Perspectives on HIV and Sexual and Reproductive Health. M-JM is supported in part by the United States National Institutes of Health (R01-DA0251525), a Scholar Award from the Michael Smith Foundation for Health Research and a New Investigator Award from CIHR. His institution has received unstructured funding to support his research from NG Biomed, Ltd.

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflicts of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178–93.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88(21):948–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Slawson G, Milloy M, Balneaves L, Simo A, Guillemi S, Hogg R, et al. High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting. AIDS Behav. 2015;19(1):120–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10(4):731–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Rosen M, Black A, Arnsten J, Goggin K, Remien R, Simoni J, et al. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav. 2013;17(1):142–7.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103(8):1457–67.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–94.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Azar P, Wood E, Nguyen P, Luma M, Montaner J, Kerr T, et al. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015;15(1):193.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health. 2004;29(2):117–27.CrossRefPubMedGoogle Scholar
  10. 10.
    Health Canada. Canadian Alcohol and Drug Use Monitoring Survey: Summary of Results for 2011. 2011. http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2011/summary-sommaire-eng.php-share.
  11. 11.
    Kalichman SC, Grebler T, Amaral CM, McNerney M, White D, Kalichman MO, et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. Int J Behav Med. 2014;21(5):811–20.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chander LB, Moore R. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection (1999). J Acquir Immune Defic Syndromes. 2006;43(4):411.CrossRefGoogle Scholar
  13. 13.
    Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis (1999). J Acquir Immune Defic Syndromes. 2009;52(2):180.CrossRefGoogle Scholar
  14. 14.
    Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retrovir. 2010;26(5):511–8.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med. 2014;37(1):1–10.CrossRefPubMedGoogle Scholar
  16. 16.
    Lake S, Kerr T, Capler R, Shoveller J, Montaner J, Milloy MJ. High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada. Int J Drug Policy. 2017;42:63–70.CrossRefPubMedGoogle Scholar
  17. 17.
    Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362(9392):1267–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996–2004. PLoS ONE. 2009;4(2):e4445.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Carrico AW. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci. 2011;88(21):940–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Machtinger E, Wilson T, Haberer JE, Weiss D. Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav. 2012;16(8):2091–100.CrossRefPubMedGoogle Scholar
  21. 21.
    Borwein A, Chan K, Palmer A, Miller C, Montaner J, Hogg R. Violence among a cohort of HIV-positive women on antiretroviral therapy in British Columbia, Canada. Oral session presented at 1st International Workshop on HIV and Women 2011, January.Google Scholar
  22. 22.
    Trimble DD, Nava A, McFarlane J. Intimate partner violence and antiretroviral adherence among women receiving care in an urban Southeastern Texas HIV clinic. J Assoc Nurses AIDS Care. 2013;24(4):331–40.CrossRefPubMedGoogle Scholar
  23. 23.
    Gruskin L, Gange SJ, Celentano D, Schuman P, Moore JS, Zierler S, et al. Incidence of violence against HIV-infected and uninfected women: findings from the HIV Epidemiology Research (HER) Study. J Urban Health. 2002;79(4):512–24.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bedimo AL, Kissinger P, Bessinger R. History of sexual abuse among HIV-infected women. Int J STD AIDS. 1997;8(5):332–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Shannon K, Kerr T, Strathdee SA, Shoveller J, Montaner JS, Tyndall MW. Prevalence and structural correlates of gender based violence among a prospective cohort of female sex workers. BMJ. 2009;339:2939–47.CrossRefGoogle Scholar
  26. 26.
    El-Bassel N, Gilbert L, Wu E, Go H, Hill J. HIV and intimate partner violence among methadone-maintained women in New York City. Soc Sci Med. 2005;61(1):171–83.CrossRefPubMedGoogle Scholar
  27. 27.
    El-Bassel N, Witte S, Wada T, Gilbert L, Wallace J. Correlates of partner violence among female street-based sex workers: substance abuse, history of childhood abuse, and HIV risks. AIDS Patient Care STDs. 2001;15(1):41–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Pearce ME, Christian WM, Patterson K, Norris K, Moniruzzaman A, Craib KJP, et al. The cedar project: historical trauma, sexual abuse and HIV risk among young aboriginal people who use injection and non-injection drugs in two Canadian cities. Soc Sci Med. 2008;66(11):2185–94.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Berger. Workable sisterhood: the political journey of stigmatized women with HIV/AIDS. Princeton: Princeton University Press; 2010.CrossRefGoogle Scholar
  30. 30.
    Logie C, James L, Tharao W, Loutfy M. HIV, gender, race, sexual orientation, and sex work: a qualitative study of intersectional stigma experienced by HIV-positive women in Ontario, Canada. PLoS Med. 2011;8(11):e1001124.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Azim T, Bontell I, Strathdee SA. Women, drugs and HIV. Int J Drug Policy. 2015;26(1):S16–21.CrossRefPubMedGoogle Scholar
  32. 32.
    Campbell JC, Baty M, Ghandour RM, Stockman JK, Francisco L, Wagman J. The intersection of intimate partner violence against women and HIV/AIDS: a review. Int J Injury Control Saf Promot. 2008;15(4):221–31.CrossRefGoogle Scholar
  33. 33.
    Hatcher AM, Smout EM, Turan JM, Christofides N, Stöckl H. Intimate partner violence and engagement in HIV care and treatment among women: a systematic review and meta-analysis. AIDS. 2015;29(16):2183–94.CrossRefPubMedGoogle Scholar
  34. 34.
    Schafer KR, Brant J, Gupta S, Thorpe J, Winstead-Derlega C, Pinkerton R, et al. Intimate partner violence: a predictor of worse HIV outcomes and engagement in care. AIDS Patient Care STDs. 2012;26(6):356–65.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Machtinger E, Haberer J, Wilson T, Weiss D. Recent trauma is associated with antiretroviral failure and HIV transmission risk behavior among HIV-positive women and female-identified transgenders. AIDS Behav. 2012;16(8):2160–70.CrossRefPubMedGoogle Scholar
  36. 36.
    Meyer JP, Springer SA, Altice FL. Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Women’s Health. 2011;20(7):991–1006.CrossRefGoogle Scholar
  37. 37.
    Sullivan KA, Messer LC, Quinlivan EB. Substance abuse, violence, and HIV/AIDS (SAVA) syndemic effects on viral suppression among HIV positive women of color. AIDS Patient Care STDs. 2015;29(S1):S42–8.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Singer M. A dose of drugs, a touch of violence, a case of AIDS: conceptualizing the SAVA syndemic. Free Inq Creative Sociol. 1996;24(2):99–110.Google Scholar
  39. 39.
    Singer M. AIDS and the health crisis of the US urban poor; the perspective of critical medical anthropology. Soc Sci Med. 1994;39(7):931–48.CrossRefPubMedGoogle Scholar
  40. 40.
    Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17(4):423–41.CrossRefPubMedGoogle Scholar
  41. 41.
    Batchelder AW, Lounsbury DW, Palma A, Carrico A, Pachankis J, Schoenbaum E, et al. Importance of substance use and violence in psychosocial syndemics among women with and at-risk for HIV. AIDS Care. 2016;28(10):1316–20.CrossRefPubMedCentralGoogle Scholar
  42. 42.
    Koblin BA, Grant S, Frye V, Superak H, Sanchez B, Lucy D, et al. HIV sexual risk and syndemics among women in three urban areas in the United States: analysis from HVTN 906. J Urban Health. 2015;92(3):572–83.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Dale S, Cohen M, Weber K, Cruise R, Kelso G, Brody L. Abuse and resilience in relation to HAART medication adherence and HIV viral load among women with HIV in the United States. AIDS Patient Care STDs. 2014;28(3):136–43.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Collins LM, Lanza ST. Latent class and latent transition analysis: with applications in the social, behavioral, and health sciences. Hoboken: Wiley; 2013.Google Scholar
  45. 45.
    Sunderland M, Chalmers J, McKetin R, Bright D. Typologies of alcohol consumption on a saturday night among young adults. Alcoholism. 2014;38(6):1745–52.CrossRefPubMedGoogle Scholar
  46. 46.
    Noor SW, Ross MW, Lai D, Risser JM. Use of latent class analysis approach to describe drug and sexual HIV risk patterns among injection drug users in Houston, Texas. AIDS Behav. 2014;18(3):276–83.CrossRefPubMedGoogle Scholar
  47. 47.
    McCarty-Caplan D, Jantz I, Swartz J. MSM and drug use: a latent class analysis of drug use and related sexual risk behaviors. AIDS Behav. 2014;18(7):1339–51.CrossRefPubMedGoogle Scholar
  48. 48.
    Newcomb ME, Ryan DT, Greene GJ, Garofalo R, Mustanski B. Prevalence and patterns of smoking, alcohol use, and illicit drug use in young men who have sex with men. Drug Alcohol Depend. 2014;141:65–71.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Lanza ST, Bray BC. Transitions in drug use among high-risk women: an application of latent class and latent transition analysis. Adv Appl Stat Sci. 2010;3(2):203–35.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Loutfy M, Greene S, Kennedy VL, Lewis J, Thomas-Pavanel J, Conway T, et al. Establishing the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS): operationalizing Community-based Research in a Large National Quantitative Study. BMC Med Res Methodol. 2016;16(1):101–10.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Loutfy M dPA, O’Brien N, Thomas-Pavanel J, Carter A, Proulx-Boucher K, Beaver K, Nicholson V, Colley G, Sereda P, Hogg RS, Kaida A, CHIWOS Research Team. The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS): an evaluation of women-centred HIV care (WCC). 5th International Workshop on HIV and Women; Seattle, WAFebruary 21-22nd, 2015.Google Scholar
  52. 52.
    Israel BA, Schulz AJ, Parker EA, Becker AB. Review of community-based research: assessing partnership approaches to improve public health. Annu Rev Public Health. 1998;19(1):173–202.CrossRefPubMedGoogle Scholar
  53. 53.
    Raphael D. Social determinants of health: Canadian perspectives. 2nd ed. Toronto: Canadian Scholars’ Press; 2009.Google Scholar
  54. 54.
    Benoit C, Shumka L. Gendering the population health perspective: fundamental determinants of women’s health. Final report prepared for the Women’s Health Research Network. Vancouver, BC; 2007.Google Scholar
  55. 55.
    De Reus LA, Few AL, Blume LB. Multicultural and critical race feminisms: theorizing families in the third wave. Sourceb Fam Theory Res. 2005. doi: 10.4135/9781412990172.n18.Google Scholar
  56. 56.
    Webster K, Carter A, Proulx-Boucher K, Dubuc D, Nicholson V, Beaver K, et al. Strategies for recruiting women living with HIV in community-based research: Lessons from Canada Progress in Community Health Partnerships: Research, Education, and Action. Accepted.Google Scholar
  57. 57.
    Palamar JJ, Davies S, Ompad DC, Cleland CM, Weitzman M. Powder cocaine and crack use in the United States: an examination of risk for arrest and socioeconomic disparities in use. Drug Alcohol Dependence. 2015;149:108–16.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Statistics Canada. Low income lines, 2013-2014: Update Ottawa, Canada: Statistics Canada; 2013.Google Scholar
  59. 59.
    Wagnild G, Young H. Development and psychometric validation of the resilience scale. J Nurs Meas. 1993;1:165–78.PubMedGoogle Scholar
  60. 60.
    Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16(2):269–77.CrossRefPubMedGoogle Scholar
  61. 61.
    Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: a SAS procedure for latent class analysis. Struct Equ Model. 2007;14(4):671–94.CrossRefGoogle Scholar
  62. 62.
    Lanza ST, Dziak JJ, Huang L, Xu S, Collins LM. PROC LCA & PROC LTA user’s guide (Version 1.3.2). University Park: The Methodology Center, Pennsylvania State University; 2015.Google Scholar
  63. 63.
    Akaike H. Factor analysis and AIC. Psychometrika. 1987;52(3):317–32.CrossRefGoogle Scholar
  64. 64.
    Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6(2):461–4.CrossRefGoogle Scholar
  65. 65.
    Bozdogan H. Model selection and Akaike’s information criterion (AIC): the general theory and its analytical extensions. Psychometrika. 1987;52(3):345–70.CrossRefGoogle Scholar
  66. 66.
    Sclove SL. Application of model-selection criteria to some problems in multivariate analysis. Psychometrika. 1987;52(3):333–43.CrossRefGoogle Scholar
  67. 67.
    Vermunt JK. Latent class modeling with covariates: two improved three-step approaches. Polit Anal. 2010;18(4):450–69.CrossRefGoogle Scholar
  68. 68.
    Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21(9):1175–83.CrossRefPubMedGoogle Scholar
  69. 69.
    Wasserstein RL, Lazar NA. The ASA’s statement on p-values: context, process, and purpose. The American Statistician. 2016.Google Scholar
  70. 70.
    Rothman KJ. Epidemiology: an introduction. New York: Oxford University Press; 2012.Google Scholar
  71. 71.
    Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002;63(2):179–86.CrossRefPubMedGoogle Scholar
  72. 72.
    Hutton HE, McCaul ME, Chander G, Jenckes MW, Nollen C, Sharp VL, et al. Alcohol use, anal sex, and other risky sexual behaviors among HIV-infected women and men. AIDS Behav. 2013;17(5):1694–704.CrossRefPubMedGoogle Scholar
  73. 73.
    Chander Josephs J, Fleishman J, Korthuis P, Gaist P, Hellinger J, et al. Alcohol use among HIV-infected persons in care: results of a multi-site survey. HIV Med. 2008;9(4):196–202.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Webb MS, Vanable PA, Carey MP, Blair DC. Cigarette smoking among HIV + men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum. J Behav Med. 2007;30(5):371–83.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100(10):1896–903.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Gerstoft J, et al. Mortality attributable to smoking among HIV-1–infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727–34.CrossRefPubMedGoogle Scholar
  77. 77.
    Hile SJ, Feldman MB, Alexy ER, Irvine MK. Recent tobacco smoking is associated with poor HIV medical outcomes among HIV-infected individuals in New York. AIDS Behav. 2016. doi: 10.1007/s10461-015-1273-x.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. JAIDS J Acquir Immune Defic Syndromes. 2004;35(1):38–45.CrossRefGoogle Scholar
  79. 79.
    Reid JL, Hammond D, Rynard VL, Burkhalter R. Tobacco use in Canada: patterns and trends. 2015th ed. Waterloo: Propel Centre for Population Health Impact, University of Waterloo; 2015.Google Scholar
  80. 80.
    Kuo I, Golin CE, Wang J, Haley DF, Hughes J, Mannheimer S, et al. Substance use patterns and factors associated with changes over time in a cohort of heterosexual women at risk for HIV acquisition in the United States. Drug Alcohol Depend. 2014;139:93–9.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Marquez C, Mitchell SJ, Hare CB, John M, Klausner JD. Methamphetamine use, sexual activity, patient–provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004–2006. AIDS Care. 2009;21(5):575–82.CrossRefPubMedGoogle Scholar
  82. 82.
    Kapadia F, Vlahov D, Wu Y, Cohen MH, Greenblatt RM, Howard AA, et al. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse. 2008;34(2):161–70.CrossRefPubMedGoogle Scholar
  83. 83.
    Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Supplement 3):S272–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on HAART, irrespective of adherence level. J Acquir Immune Defic Syndromes. 2010;55(4):460.CrossRefGoogle Scholar
  85. 85.
    Günthard HF, Saag MS, Benson CA, Rio C, Eron JJ, Gallant JE. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA Panel. JAMA. 2016;2016:316.Google Scholar
  86. 86.
    Brizay U, Golob L, Globerman J, Gogolishvili D, Bird M, Rios-Ellis B, et al. Community-academic partnerships in HIV-related research: a systematic literature review of theory and practice. J Int AIDS Soc. 2015;18(1):19354.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Parashar S, Palmer AK, O’Brien N, Chan K, Shen A, Coulter S, et al. Sticking to it: the effect of maximally assisted therapy on antiretroviral treatment adherence among individuals living with HIV who are unstably housed. AIDS Behav. 2011;15(8):1612.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Maru DS-R, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, et al. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav. 2008;12(2):284–93.CrossRefPubMedGoogle Scholar
  89. 89.
    Macalino GE, Hogan JW, Mitty JA, Bazerman LB, DeLong AK, Loewenthal H, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS. 2007;21(11):1473–7.CrossRefPubMedGoogle Scholar
  90. 90.
    Altice FL, Maru DS-R, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45(6):770–8.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Lappalainen L, Nolan S, Dobrer S, Puscas C, Montaner J, Ahamad K, et al. Dose–response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction. 2015;110(8):1330–9.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Vancouver Coastal Health. Insite - Supervised Injection Site 2016. http://supervisedinjection.vch.ca.
  93. 93.
    British Columbia Ministry of Health. Integrated models of primary care and mental health & substance use care in the community: literature review and guiding document. Vancouver: British Columbia Ministry of Health; 2012.Google Scholar
  94. 94.
    British Columbia Centre of Excellence for Women’s Health. Women-centred harm reduction: gendering the national framework. Vancouver: British Columbia Centre of Excellence for Women’s Health; 2012.Google Scholar
  95. 95.
    Kamarulzaman A, Altice FL. The challenges in managing HIV in people who use drugs. Curr Opin Infect Dis. 2015;28(1):10.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Allison Carter
    • 1
    • 2
  • Eric Abella Roth
    • 3
    • 4
  • Erin Ding
    • 2
  • M-J Milloy
    • 2
    • 5
    • 6
  • Mary Kestler
    • 7
    • 8
  • Shahab Jabbari
    • 2
  • Kath Webster
    • 1
  • Alexandra de Pokomandy
    • 9
    • 10
  • Mona Loutfy
    • 11
  • Angela Kaida
    • 1
    • 12
    Email author
  • Behalf of the CHIWOS Research Team
  1. 1.Faculty of Health SciencesSimon Fraser UniversityBurnabyCanada
  2. 2.British Columbia Centre for Excellence in HIV/AIDSVancouverCanada
  3. 3.Centre for Addictions Research of British ColumbiaUniversity of VictoriaVictoriaCanada
  4. 4.Department of AnthropologyUniversity of VictoriaVictoriaCanada
  5. 5.Division of AIDS, Department of MedicineUniversity of British ColumbiaVancouverCanada
  6. 6.British Columbia Centre on Substance UseVancouverCanada
  7. 7.Oak Tree ClinicBC Women’s Health CentreVancouverCanada
  8. 8.Division of Infectious Diseases, Department of MedicineUniversity of British ColumbiaVancouverCanada
  9. 9.McGill University Health CentreMontrealCanada
  10. 10.Department of Family MedicineMcGill UniversityMontrealCanada
  11. 11.Women’s College Research InstituteWomen’s College HospitalTorontoCanada
  12. 12.Faculty of Health SciencesSimon Fraser UniversityBurnabyCanada

Personalised recommendations